MDNA209 is a potential first-in-class engineered Superkine designed to block CD122 and simultaneously inhibit IL-2 and IL-15 signaling to modulate an overactive immune systemTORONTO and HOUSTON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines for cancer and autoimmune diseases, today announced that it will present new preclinical data on MDNA209, its potential first-in-class ...